Opinion|Videos|July 3, 2024
Supportive Care Strategies for CAR T-Cell Therapy Recipients
Experts on multiple myeloma provide clinical insights on supportive care strategies for patients experiencing infections or secondary malignancies following CAR T-cell therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Discuss the importance of comprehensive supportive care strategies for CAR T-cell therapy recipients to mitigate risks and optimize outcomes.
Advertisement
Related to this article
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.
Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.
Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Ralph V. Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration multiple myeloma care.
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Ris-Rez Produces Antitumor Activity in Extensive-Stage SCLC
3
The Gynecologic Oncology Data to Watch at ESMO 2026: De-Escalation and ADCs
4
Cancer Vaccine Combinations Improve 1-Year Survival in Second-Line NSCLC
5